secwatch.observer — SEC 8-K summary
======================================

Issuer:     Entrada Therapeutics, Inc. (TRDA)
CIK:        0001689375
Form:       8-K
Filed at:   2024-03-13T23:59:59+00:00
Accession:  0001689375-24-000014
Event type: earnings
Sentiment:  positive
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Entrada Therapeutics FY2023 net loss $6.7M, cash $352M; DMD Phase 1 data on track
--------------------------------------------------------------------------------

- Cash, equivalents and marketable securities $352.0M as of Dec 31, 2023, up from $188.7M; runway through Q2 2026.
- Collaboration revenue $129.0M full year (Vertex deal); net loss narrowed to $6.7M from $94.6M in 2022.
- Completed dosing first three cohorts of ENTR-601-44 Phase 1 for DMD; data readout H2 2024.
- Regulatory applications expected Q4 2024 for global Phase 2 of ENTR-601-44 and ENTR-601-45.
- Promoted Nathan Dowden to President & COO; appointed Kevin Healy (SVP Regulatory) and Marie Rosenfeld (SVP Clinical Ops).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/0001689375-24-000014-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1689375/000168937524000014/trda-20240313.htm
  HTML page:      https://secwatch.observer/filing/0001689375-24-000014

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer